Emodin inhibits the growth of hepatoma cells: Finding the common anti-cancer pathway using Huh7, Hep3B, and HepG2 cells

Biochemical and Biophysical Research Communications

Volumn 392, Issue 4, 2010, Pages 473-478

  Hsu, Chin Mu ^a,b   Hsu, Yu An ^c   Tsai, Yuhsin ^a   Shieh, Fa Kuen ^d   Huang, Su Hua ^e   Wan, Lei ^a,b,e   Tsai, Fuu Jen ^a,b  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^d NATIONAL CENTRAL UNIVERSITY   (Taiwan)

^e ASIA UNIVERSITY   (Taiwan)

Author keywords

Anti cancer drug; Emodin; G2 M arrest; Hepatocellular carcinoma

Indexed keywords

BIOLOGICAL MARKER; CHECKPOINT KINASE 2; COMPLEMENTARY DNA; CYCLIN A; CYCLIN B; CYCLIN DEPENDENT KINASE 2; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; EMODIN; GROWTH DIFFERENTIATION FACTOR 15; MESSENGER RNA; PROTEIN P27; SOS PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; DNA MICROARRAY; GROWTH INHIBITION; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHUBARB; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; EMODIN; GENE EXPRESSION; GENE EXPRESSION PROFILING; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN KINASE INHIBITORS;

RHEUM PALMATUM;

EID: 76749138374     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.10.153     Document Type: Article

References (18)

1. Wang S.C., Zhang L., Hortobagyi G.N., and Hung M.C. Targeting HER2: recent developments and future directions for breast cancer patients. Semin. Oncol. 28 (2001) 21-29
2. Su Y.T., Chang H.L., Shyue S.K., and Hsu S.L. Emodin induces apoptosis in human lung adenocarcinoma cells through a reactive oxygen species-dependent mitochondrial signaling pathway. Biochem. Pharmacol. 70 (2005) 229-241
3. Chen Y.C., Shen S.C., Lee W.R., Hsu F.L., Lin H.Y., Ko C.H., and Tseng S.W. Emodin induces apoptosis in human promyeloleukemic HL-60 cells accompanied by activation of caspase 3 cascade but independent of reactive oxygen species production. Biochem. Pharmacol. 64 (2002) 1713-1724
4. Shieh D.E., Chen Y.Y., Yen M.H., Chiang L.C., and Lin C.C. Emodin-induced apoptosis through p53-dependent pathway in human hepatoma cells. Life Sci. 74 (2004) 2279-2290
5. Muto A., Hori M., Sasaki Y., Saitoh A., Yasuda I., Maekawa T., Uchida T., Asakura K., Nakazato T., Kaneda T., Kizaki M., Ikeda Y., and Yoshida T. Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor. Mol. Cancer Ther. 6 (2007) 987-994
6. Lu H.F., Lai K.C., Hsu S.C., Lin H.J., Kuo C.L., Liao C.L., Yang J.S., and Chung J.G. Involvement of matrix metalloproteinases on the inhibition of cells invasion and migration by emodin in human neuroblastoma SH-SY5Y cells. Neurochem. Res. 34 (2009) 1575-1583
7. Battistutta R., Sarno S., De Moliner E., Papinutto E., Zanotti G., and Pinna L.A. The replacement of ATP by the competitive inhibitor emodin induces conformational modifications in the catalytic site of protein kinase CK2. J. Biol. Chem. 275 (2000) 29618-29622
8. D.M. Parkin, F. Bray, J. Ferlay, P. Pisani, Global cancer statistics, 2002, CA Cancer J. Clin. 55 (2005) 74-108.
9. Raoul J.L. Natural history of hepatocellular carcinoma and current treatment options. Semin. Nucl. Med. 38 (2008) S13-S18
10. Pisani P., Bray F., and Parkin D.M. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int. J. Cancer 97 (2002) 72-81
11. Harbig J., Sprinkle R., and Enkemann S.A. A sequence-based identification of the genes detected by probesets on the Affymetrix U133 plus 2.0 array. Nucleic Acids Res. 33 (2005) e31
12. Rozenblat S., Grossman S., Bergman M., Gottlieb H., Cohen Y., and Dovrat S. Induction of G2/M arrest and apoptosis by sesquiterpene lactones in human melanoma cell lines. Biochem. Pharmacol. 75 (2008) 369-382
13. Smits V.A., and Medema R.H. Checking out the G(2)/M transition. Biochim. Biophys. Acta 1519 (2001) 1-12
14. Pines J., and Hunter T. Isolation of a human cyclin cDNA: evidence for cyclin mRNA and protein regulation in the cell cycle and for interaction with p34cdc2. Cell 58 (1989) 833-846
15. Schwartz G.K. Development of cell cycle active drugs for the treatment of gastrointestinal cancers: a new approach to cancer therapy. J. Clin. Oncol. 23 (2005) 4499-4508
16. Oyama T., Kagawa N., Kunugita N., Kitagawa K., Ogawa M., Yamaguchi T., Suzuki R., Kinaga T., Yashima Y., Ozaki S., Isse T., Kim Y.D., Kim H., and Kawamoto T. Expression of cytochrome P450 in tumor tissues and its association with cancer development. Front. Biosci. 9 (2004) 1967-1976
17. Osborne C.K. Tamoxifen in the treatment of breast cancer. N. Engl. J. Med. 339 (1998) 1609-1618
18. Feng P., Wang B., and Ren E.C. Cyr61/CCN1 is a tumor suppressor in human hepatocellular carcinoma and involved in DNA damage response. Int. J. Biochem. Cell Biol. 40 (2008) 98-109